Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016 Read more about Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016
Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting Read more about Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting
Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195 Read more about Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195
Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies Read more about Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Reports Second Quarter 2016 Financial Results Read more about Xencor Reports Second Quarter 2016 Financial Results
Xencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016 Read more about Xencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016
Xencor Provides Updates on Lead Programs and Reviews Bispecific Oncology Partnership; Announces Expansion of Bispecific Oncology Pipeline at Analyst Day Read more about Xencor Provides Updates on Lead Programs and Reviews Bispecific Oncology Partnership; Announces Expansion of Bispecific Oncology Pipeline at Analyst Day
Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676 Read more about Xencor Announces Strategic Collaboration for Bispecific Programs, including XmAb 14045 and XmAb 13676
